AusBiotech

The Leukaemia Foundation has announced the latest round of research funded through Cancer Australia’s priority-driven Collaborative Cancer Research Scheme. 

Australian preclinical drug development company Nyrada (ASX:NYR) has provided an update on the progress of its small molecule cholesterol-lowering program. 

Race Oncology (ASX:RAC) says it has received binding commitments to raise $5.4 million before costs in an oversubscribed equity placement to new and existing institutional and sophisticated investors.

Neurotech International (ASX:NTI) has announced the commencement of a phase 1/2 open-label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder.

In less than two weeks hundreds will gather for Australia’s premier medical technology conference, which will reconnect key stakeholders of the Australian devices and diagnostics sector to help reimagine the industry during a changing landscape. Business partnering will open in less than one week.

A drug candidate discovered by the Australian company Pharmaxis (ASX:PXS) will be the focus of a new trial aimed at studying its potential as a treatment for an aggressive and deadly form of brain cancer.

AusBiotech is inviting expressions of interest from its corporate members for its new virtual pitching series, BiotechPitch. Its new platform will profile Australian companies to investors internationally and will feature expert industry speakers and commentators offering capital insights and market updates.

Australian clinical dermatology and antimicrobial company Botanix Pharmaceuticals (ASX:BOT) has released a clinical development update of its antimicrobial platform with the identification of a potential new indication.

Medibio (ASX:MEB) says it has been awarded a patent from the US Patent and Trademark Office for its 'Method and System for Assessing Mental State'.

Recce Pharmaceuticals (ASX:RCE) has announced that its RECCE 327 has demonstrated bactericidal activity against all six antibiotic-resistant ESKAPE pathogens, including drug-resistant mutations as well as two additional WHO priority pathogens list.

CSL has announced $2 million in total funding over two years for four Australian projects under its Research Acceleration Initiative partnership.

Private medical technology companies Epiminder and Seer Medical have announced a collaboration to accelerate ultra-long term EEG monitoring so those people who suffer seizures may have an advanced digital therapeutics product to detect and forecast their seizures.